The explosive growth of novel cancer therapies in the last decade has led to dramatic
improvements in the survival of patients with cancer. 1 The occurrence of poorly understood …

Cancer therapies can cause a variety of cardiac toxicities, including ischemia,
cardiomyopathy, heart failure, myocarditis, arrhythmias, vascular disease, hypertension, and …

Combined modality approaches to cancer treatment have dramatically improved clinical
outcomes. At the same time, there has been increased attention to acute, chronic, and late …

Progress in the detection and treatment of cancer has led to an impressive reduction in both
mortality and morbidity. Due to their mechanism of action, however, conventional …

Improving cancer survival represents the most significant effect of precision medicine and
personalized molecular and immunologic therapeutics. Cardiovascular health becomes …

The term 'Cardio-oncology'was coined at European Institute of Oncology in 1995 and made
official in 1996 with the first publication on this topic. 1 Cardio-oncology is a new …

Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent
advances in oncologic therapies have resulted in improved cancer outcomes but also a new …

Session III of the Second International Colloquium on Cardio-Oncology focused on the
diagnosis, management, and prevention of cardiovascular toxicity of cancer drugs. With a …

Cardio-oncology represents the intersection of cardiology and oncology and has emerged
as a new clinical discipline in cardiovascular medicine for several reasons (Figure 1) …

Improvements in early diagnosis and cancer treatments have contributed to high survival
rates for many cancer patients. However, these patients often die of cardiovascular disease …